User login
Key clinical point: Atopic dermatitis (AD) is associated with a lower risk for venous thromboembolism (VTE) than several rheumatologic and gastrointestinal immune-mediated inflammatory diseases (IMID).
Major finding: Patients with AD vs AD-matched control individuals did not have a higher risk for VTE (adjusted hazard ratio [aHR] 0.96; 95% CI 0.90-1.02). Compared with patients having AD, those with Crohn’s disease (aHR 1.71; 95% CI 1.47-1.99), rheumatoid arthritis (aHR 1.57; 95% CI 1.43-1.72), ulcerative colitis (aHR 1.84; 95% CI 1.63-2.09), and ankylosing spondylitis (aHR 1.45; 95% CI 1.03-2.03) had higher risks for VTE.
Study details: This retrospective observational cohort study analyzed 2,061,222 adult patients with IMID, including 1,098,633 patients with AD who were matched with 1,098,633 control individuals without IMID.
Disclosures: This study was funded by AbbVie Inc. JF Merola declared being a consultant or investigator for AbbVie and others. The other authors declared being current or former employees of or owning stocks or stock options in AbbVie.
Source: Merola JF et al. Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data. J Am Acad Dermatol. 2023 (Dec 23). doi: 10.1016/j.jaad.2023.12.027
Key clinical point: Atopic dermatitis (AD) is associated with a lower risk for venous thromboembolism (VTE) than several rheumatologic and gastrointestinal immune-mediated inflammatory diseases (IMID).
Major finding: Patients with AD vs AD-matched control individuals did not have a higher risk for VTE (adjusted hazard ratio [aHR] 0.96; 95% CI 0.90-1.02). Compared with patients having AD, those with Crohn’s disease (aHR 1.71; 95% CI 1.47-1.99), rheumatoid arthritis (aHR 1.57; 95% CI 1.43-1.72), ulcerative colitis (aHR 1.84; 95% CI 1.63-2.09), and ankylosing spondylitis (aHR 1.45; 95% CI 1.03-2.03) had higher risks for VTE.
Study details: This retrospective observational cohort study analyzed 2,061,222 adult patients with IMID, including 1,098,633 patients with AD who were matched with 1,098,633 control individuals without IMID.
Disclosures: This study was funded by AbbVie Inc. JF Merola declared being a consultant or investigator for AbbVie and others. The other authors declared being current or former employees of or owning stocks or stock options in AbbVie.
Source: Merola JF et al. Venous thromboembolism risk is lower in patients with atopic dermatitis than other immune-mediated inflammatory diseases: A retrospective, observational, comparative cohort study using US claims data. J Am Acad Dermatol. 2023 (Dec 23). doi: 10.1016/j.jaad.2023.12.027
Key clinical point: Atopic dermatitis (AD) is associated with a lower risk for venous thromboembolism (VTE) than several rheumatologic and gastrointestinal immune-mediated inflammatory diseases (IMID).
Major finding: Patients with AD vs AD-matched control individuals did not have a higher risk for VTE (adjusted hazard ratio [aHR] 0.96; 95% CI 0.90-1.02). Compared with patients having AD, those with Crohn’s disease (aHR 1.71; 95% CI 1.47-1.99), rheumatoid arthritis (aHR 1.57; 95% CI 1.43-1.72), ulcerative colitis (aHR 1.84; 95% CI 1.63-2.09), and ankylosing spondylitis (aHR 1.45; 95% CI 1.03-2.03) had higher risks for VTE.
Study details: This retrospective observational cohort study analyzed 2,061,222 adult patients with IMID, including 1,098,633 patients with AD who were matched with 1,098,633 control individuals without IMID.
Disclosures: This study was funded by AbbVie Inc. JF Merola declared being a consultant or investigator for AbbVie and others. The other authors declared being current or former employees of or owning stocks or stock options in AbbVie.